Type d'article
Etat
Reliure
Particularités
Livraison gratuite
Pays
Evaluation du vendeur
Edité par Independently published, 2024
Vendeur : California Books, Miami, FL, Etats-Unis
Livre impression à la demande
Etat : New. Print on Demand.
Edité par Independently published, 2024
Vendeur : California Books, Miami, FL, Etats-Unis
Livre impression à la demande
Etat : New. Print on Demand.
Edité par Chan-ok, 2010
ISBN 10 : 2916899421ISBN 13 : 9782916899428
Vendeur : RECYCLIVRE, Paris, France
Livre
Etat : Bon. Attention: Ancien support de bibliothèque, plastifié, étiquettes. Merci, votre achat aide à financer des programmes de lutte contre l'illettrisme.
Edité par Cambridge University Press, 2023
ISBN 10 : 1009342304ISBN 13 : 9781009342308
Vendeur : GreatBookPrices, Columbia, MD, Etats-Unis
Livre
Etat : New.
Edité par Cambridge University Press 1/26/2023, 2023
ISBN 10 : 1009342304ISBN 13 : 9781009342308
Vendeur : BargainBookStores, Grand Rapids, MI, Etats-Unis
Livre
Paperback or Softback. Etat : New. Egfr-Directed Therapy in Lung Cancer 0.16. Book.
Edité par Cambridge University Press, 2023
ISBN 10 : 1009342304ISBN 13 : 9781009342308
Vendeur : GreatBookPrices, Columbia, MD, Etats-Unis
Livre
Etat : As New. Unread book in perfect condition.
Edité par Cambridge University Press, 2023
ISBN 10 : 1009342304ISBN 13 : 9781009342308
Vendeur : booksXpress, Bayonne, NJ, Etats-Unis
Livre impression à la demande
Soft Cover. Etat : new. This item is printed on demand.
Edité par Cambridge University Press, Cambridge, 2023
ISBN 10 : 1009342304ISBN 13 : 9781009342308
Vendeur : Grand Eagle Retail, Wilmington, DE, Etats-Unis
Livre
Paperback. Etat : new. Paperback. Epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) is a clinically important driver alteration affecting approximately one-third of lung cancer patients. Treatments for EGFR-exon 19 deletion and exon 21 L858R NSCLC have evolved over the last decade from first-generation reversible tyrosine kinase inhibitors (TKI) to third-generation irreversible TKIs, of which osimertinib has been the widely accepted as first-line therapy. Despite survival improvement seen with osimertinib and its efficacy against acquired T790M mutation, resistance through on-target and off-target pathways eventually develop. This Element describes the structural biology and pathophysiology of EGFR-mutant NSCLC and discusses past, current, and future treatment options in the metastatic, neoadjuvant, and adjuvant settings. It describes the biology and recently approved treatment for EGFR-exon 20 insertion mutation and the treatment for the uncommon exon 18 (G719X), 20 (S768I), and 21 (L861Q) mutations. It also outlines the promising clinical applications of circulating tumor DNA (ctDNA). This Element describes the structural biology and pathophysiology of EGFR-mutant NSCLC and describes past, current, and future treatment options in different settings. It discusses the biology and recently approved treatment for EGFR-exon 20 insertion mutation and the treatment for the uncommon mutations. Shipping may be from multiple locations in the US or from the UK, depending on stock availability.
Edité par Cambridge University Press, 2023
ISBN 10 : 1009342304ISBN 13 : 9781009342308
Vendeur : Revaluation Books, Exeter, Royaume-Uni
Livre
Paperback. Etat : Brand New. 75 pages. 8.94x5.98x0.24 inches. In Stock.
Edité par Cambridge University Press, 2023
ISBN 10 : 1009342304ISBN 13 : 9781009342308
Vendeur : Revaluation Books, Exeter, Royaume-Uni
Livre
Paperback. Etat : Brand New. 75 pages. 8.94x5.98x0.24 inches. In Stock.
Edité par Cambridge University Press, 2023
ISBN 10 : 1009342304ISBN 13 : 9781009342308
Vendeur : THE SAINT BOOKSTORE, Southport, Royaume-Uni
Livre impression à la demande
Paperback / softback. Etat : New. This item is printed on demand. New copy - Usually dispatched within 5-9 working days.
Edité par Cambridge University Press, 2023
ISBN 10 : 1009342304ISBN 13 : 9781009342308
Vendeur : Brook Bookstore On Demand, Napoli, NA, Italie
Livre impression à la demande
Etat : new. Questo è un articolo print on demand.
Edité par Cambridge University Press, 2023
ISBN 10 : 1009342304ISBN 13 : 9781009342308
Vendeur : Russell Books, Victoria, BC, Canada
Livre
Etat : New. Special order direct from the distributor.
Edité par Cambridge University Press, 2023
ISBN 10 : 1009342304ISBN 13 : 9781009342308
Vendeur : GreatBookPricesUK, Castle Donington, DERBY, Royaume-Uni
Livre
Etat : New.
Edité par A walk of mind, 2018
ISBN 10 : 8960903620ISBN 13 : 9788960903623
Vendeur : ThriftBooks-Atlanta, AUSTELL, GA, Etats-Unis
Livre
Hardcover. Etat : Very Good. No Jacket. May have limited writing in cover pages. Pages are unmarked. ~ ThriftBooks: Read More, Spend Less 1.01.
Edité par Cambridge University Press, 2023
ISBN 10 : 1009342304ISBN 13 : 9781009342308
Vendeur : GreatBookPricesUK, Castle Donington, DERBY, Royaume-Uni
Livre
Etat : As New. Unread book in perfect condition.
Edité par Cambridge University Press, 2023
ISBN 10 : 1009342304ISBN 13 : 9781009342308
Vendeur : moluna, Greven, Allemagne
Livre impression à la demande
Kartoniert / Broschiert. Etat : New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Inhaltsverzeichnis1.Structural biology and mechanism of activation of EGFR 2. EGFR-associated oncogenesis 3. Tyrosine kinase inhibitors (TKIs) as targeted treatment for EGFR-mutant NSCLC 4. EGFR-TKIs as adjuvant or neoadjuvant therapy.